|1.||Livingston, Philip O: 11 articles (01/2012 - 10/2003)|
|2.||Ragupathi, Govind: 10 articles (01/2012 - 10/2003)|
|3.||Figdor, Carl G: 8 articles (03/2013 - 11/2003)|
|4.||Adema, Gosse J: 7 articles (03/2013 - 11/2003)|
|5.||Lesterhuis, W Joost: 7 articles (03/2013 - 11/2003)|
|6.||de Vries, I Jolanda M: 7 articles (03/2013 - 11/2003)|
|7.||Punt, Cornelis J A: 6 articles (01/2013 - 11/2003)|
|8.||McFadden, David W: 6 articles (11/2007 - 11/2003)|
|9.||Kwak, Larry W: 5 articles (06/2012 - 06/2006)|
|10.||Hood, Chandra: 5 articles (01/2012 - 11/2003)|
03/15/2001 - "We have evaluated whether the addition of a foreign helper protein, keyhole limpet hemocyanin (KLH), can augment the efficacy of tumor lysate-pulsed dendritic cells and peptide-pulsed DC immunizations in vivo. "
08/01/1990 - "Id vaccination with keyhole limpet hemocyanin-conjugated Id induced protection against a subsequent lethal tumor challenge. "
01/01/2014 - "Keyhole limpet hemocyanin (KLH) is a popular tumor vaccine carrier protein and an immunostimulant. "
01/01/2013 - "Twenty-one patients were entered onto our vaccination protocol using autologous DCs pulsed with autologous tumor lysate and keyhole limpet hemocyanin. "
01/01/2007 - "BiovaxID is a patient-specific therapeutic cancer vaccine composed of the tumor idiotype conjugated to a carrier protein, keyhole limpet hemocyanin (KLH). "
|2.||Urinary Bladder Neoplasms (Bladder Cancer)
01/01/2000 - "Keyhole limpet hemocyanin (KLH) is a nonspecific immunomodulator, demonstrated to be clinically effective in superficial bladder cancer. "
01/01/2000 - "Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results."
06/01/1994 - "The antitumor activity and potential toxicity of a clinical-grade keyhole limpet hemocyanin preparation (KLH-Immune Activator; KLH-IA) were determined in the MB-49 intravesical murine bladder tumor model. "
03/01/1993 - "Keyhole limpet hemocyanin (KLH) is a potent immunogen that is being evaluated as an immunotherapeutic alternative to BCG in the treatment of bladder cancer. "
01/01/2000 - "Since the serendipitous observation by Olsson in 1974 that patients immunized with 5 mg of keyhole limpet hemocyanin (KLH) had a marked reduction in recurrence of superficial bladder cancer, multiple laboratory and clinical studies have confirmed the efficacy of KLH immunotherapy. "
|3.||Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
06/01/2012 - "When conjugated to the immune carrier keyhole limpet hemocyanin (KLH), vaccination with an idiotype protein vaccine has been able to improve length of freedom from disease relapse in patients with follicular lymphoma (FL) in a minimal residual disease (MRD) state after induction therapy, as demonstrated in a recent randomized, controlled phase III trial. "
06/20/2009 - "To evaluate patient-specific immunotherapy with mitumprotimut-T (idiotype keyhole limpet hemocyanin [Id-KLH]) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in CD20(+) follicular lymphoma. "
06/01/2006 - "Administration of autologous tumor-derived idiotype protein conjugated to a carrier protein, keyhole limpet hemocyanin, together with granulocyte-macrophage colony-stimulating factor to follicular lymphoma patients in complete clinical remission was associated with induction of tumor-specific cellular and humoral immunity, molecular remissions, and prolonged disease-free survival. "
06/01/2011 - "Early stage clinical studies revealed that vaccination consisting of keyhole limpet hemocyanin-conjugated lymphoma idiotype protein in combination with granulocyte-macrophage colony-stimulating factor induced tumor-specific immune responses and molecular remission in patients with follicular lymphoma. "
07/10/2011 - "Vaccination with hybridoma-derived autologous tumor immunoglobulin (Ig) idiotype (Id) conjugated to keyhole limpet hemocyanin (KLH) and administered with granulocyte-monocyte colony-stimulating factor (GM-CSF) induces follicular lymphoma (FL) -specific immune responses. "
|4.||Melanoma (Melanoma, Malignant)
09/01/2010 - "The in vivo effect of these GCJs on mouse melanoma model was determined when administered either alone or in combination with non-specific immunostimulator keyhole limpet hemocyanin (KLH). "
11/01/2007 - "We have previously demonstrated the potent in vitro antiproliferative effects of keyhole limpet hemocyanin (KLH) against melanoma. "
11/01/2007 - "Keyhole limpet hemocyanin: an effective adjunct against melanoma in vivo."
11/01/2005 - "We hypothesized that keyhole limpet hemocyanin (KLH) would reduce cellular proliferation and effect apoptosis of melanoma cell lines in vitro. "
10/15/1997 - "CD4+ T cell sensitization to keyhole limpet hemocyanin and CD8+ T cell sensitization to MART-1 melanoma-associated peptide were achieved in a single culture stimulation. "
|5.||Transitional Cell Carcinoma
03/01/1995 - "In regard to this finding, we investigated the mechanisms of specific immunotherapy with keyhole-limpet hemocyanin in schistosomal associated transitional cell carcinoma. "
09/01/1986 - "Immunotherapy with bacillus Calmette-Guerin (BCG), Corynebacterium parvum (CP), keyhole limpet hemocyanin (KLH) and an extract of Allium sativum (AS) was studied in a transitional cell carcinoma (MBT-2) in mice. "
01/01/1983 - "Keyhole-limpet haemocyanin (KLH) immunotherapy of murine transitional cell carcinoma."
01/01/1991 - "In a prospective randomised controlled study, the efficacy of ethoglucid was compared with that of keyhole-limpet haemocyanin (KLH) in preventing recurrent tumours following transurethral resection of primary superficial transitional cell carcinoma of the bladder. "
12/01/2006 - "Since keyhole limpet hemocyanin (Pierce, Rockford, Illinois) is used increasingly in biomedicine as a carrier for vaccines and an immunotherapeutic agent for bladder transitional cell carcinoma, there is a growing interest in finding new substances that share its potent immunomodulatory properties. "
|2.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|4.||QS 21 (QS21)
|8.||Immunologic Adjuvants (Immunologic Adjuvant)
|10.||Bovine Serum Albumin
|3.||Drug Therapy (Chemotherapy)